Profacgen Updated Its Induced Protein Degradation Service for Drug Development

November 07 22:15 2019
Profacgen offers a wide range of services that aim to help its customers construct new protein degraders as therapeutic agents and diagnostic tools.

Profacgen, a state-of-the-art service provider that is dedicated to delivering the most up-to-date technologies, tools and expertise, is glad to update its induced protein degradation service recently to help address the unmet medical challenges. The company now offers a wide range of services that aim to help its customers construct new protein degraders as therapeutic agents and diagnostic tools.

With the rapid development of theoretical and experimental techniques of genomics and proteomics, many non-enzymatic proteins have been identified as drug targets. These non-enzymatic protein drug targets are difficult to design and discover disease therapeutics in a traditional, active-site-occupied regulatory manner. In recent years, the use of the body’s own ubiquitin-proteasome system to induce targeted protein degradation can achieve effective inhibition of many non-enzymatic proteins, which has become a new bright spot in innovative drug research.

This approach achieves ubiquitination of specific proteins of interest and finally induces degradation of the protein of interest by designing conjugates that target induced protein degradation, which contain bifunctional units to recognize and bind the protein of interest and ubiquitin E3 ligase, respectively, to induce assembly of the ubiquitination complex. This strategy of direct regulation of protein content by innovative drugs greatly expands the range of potential drug targets and provides a broad new idea for innovative drug research.

Service range of Profacgen:

Proteolysis Targeting Chimera (PROTAC) –

PROTAC is used to selectively degrade any protein of interest by bringing the target protein into proximity of the E3 ligase for proteasome-mediated proteolysis.

Hydrophobic tag –

Hydrophobic tag has been discovered to enable small-molecule control over the target protein in the absence of a direct ligand, providing an ideal way to study and validate potential drug targets in various disease models.

Destabilization domains

This approach enables the regulation of secreted proteins and their biological activity, which opens up new avenues for various applications such as cancer therapy and targeted gene delivery.

More information regarding Profacgen’s induced protein degradation services can be visited at:

About Profacgen

Profacgen is a state-of-the-art protein service provider located in Long Island, NY, USA. We provide custom protein services in the biological sciences, enabling access to the latest tools, techniques, and expertise with competitive pricing and rapid turnaround time. We are equipped with a professional team focusing on protein interaction analysis. We provide a comprehensive list of assays from initial screening (Y2H screening; Pull-down couple with MS analysis) to interaction validation (Co-IP, FRET etc.) to affinity and binding kinetics study (SPR analysis).

Media Contact
Company Name: Profacgen
Contact Person: Ellen Burns
Email: Send Email
Phone: 1-631-619-7922
Country: United States